Table 1.
Patient characteristics.
| Study population | GvHD population | p Value | |
|---|---|---|---|
| n | 17 | 22 | |
| Age | 56 (33–72) | 53 (10–72) | 0.148 |
| Sex (female/male) | 5/12 | 8/14 | 0.740 |
| Diagnosis | 0.945 | ||
| Acute leukemia | 6 | 6 | |
| Chronic leukemia | 2 | 2 | |
| Lymphoma | 2 | 3 | |
| MDS/MPN | 6 | 8 | |
| Myeloma | 0 | 1 | |
| Non-malignant | 1 | 2 | |
| Stage (early/late) | 6/11 | 7/15 | 1.000 |
| Donor (SIB/MUD/Twin/Haplo) | 2/14/1/0 | 9/12/0/1 | 0.108 |
| BM/PBSCs | 1/16 | 3/19 | 0.618 |
| CD34+ cell dose (×106/kg) | 7.7 (1.7–11.6) | 6.0 (1.4–13.3) | 0.049 |
| GvHD prophylaxis: CsA + MTX/Tac + Sir/PT Cy | 11/4/1 | 14/7/1 | 0.888 |
| MAC/RIC | 6/11 | 6/16 | 0.73 |
| TBI/chemo based | 3/14 | 7/15 | 0.464 |
| ATG (yes/no) | 13/4 | 13/9 | 0.318 |
| aGvHD (0/I/II/III) | 11/6/0/0 | 0/0/3/19 | <0.0001 |
| cGvHD (none/mild/moderate/severe) | 15/2/0/0 | 9/9/3/1 | 0.024 |
MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; SIB, sibling donor; MUD, matched unrelated donor; BM, bone marrow stem cells; PBSCs, peripheral blood stem cells; CsA + MTX, cyclosporine A + methotrexate; Tac + Sir, tacrolimus + sirolimus; PT Cy, post-transplant cyclophosphamide; MAC, myeloablative conditioning; RIC, reduced intensity conditioning; TBI, total body irradiation; ATG, anti-thymocyte globulin; GvHD, graft-versus-host disease.